AbbVie
ABBV
$136.19
Share price
-1.00%
Change (1 day)
-7.59%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $240.27 Billion
As of May 2023 AbbVie has a market cap of $240.27 Billion. This makes AbbVie the world's 35th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AbbVie from 2012 to 2023
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2023 | $240.27 B | -15.93% |
| 2022 | $285.80 B | 19.4% |
| 2021 | $239.37 B | 26.54% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On May 29th, 2023 the market cap of AbbVie was reported to be:
$242.69 Billion
$242.69 Billion
$242.67 Billion
$242.69 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $209.80 B | -12.68% | 🇺🇸 USA |
 Eli Lilly LLY | $406.06 B | 69.00% | 🇺🇸 USA |
 Amgen AMGN | $116.90 B | -51.35% | 🇺🇸 USA |
 Biogen BIIB | $43.21 B | -82.02% | 🇺🇸 USA |
 Gilead Sciences GILD | $95.53 B | -60.24% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $133.88 B | -44.28% | 🇺🇸 USA |
 AstraZeneca AZN | $221.70 B | -7.73% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $69.27 B | -71.17% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $8.72 B | -96.37% | 🇺🇸 USA |